Trial Information
A Phase 2, Open-Label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Sponsor: BRISTOL-MYERS SQUIBB
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
